Abstract: A cosmetic or pharmaceutical composition, to be applied topically is described, which has a hydrophilic outer phase, at least one cosmetic and/or pharmaceutical active ingredient and at least one carrier substance for the active ingredient. The carrier substance here forms such structures, which comprises at least two lamellar double membrane layers arranged one over another in the manner of a sandwich, wherein between adjacent double membrane layers, aligned parallel to each other, a layer of an inner phase is respectively arranged.

Abstract: A boron nitride powder including flat-shaped primary particles of BN and an aggregate of the primary particles has a water permeation speed less than 1 mm2/s and oil absorption of 100 ml/100 g to 500 ml/100 g, which is a cosmetic boron nitride powder excellent in water repellency and oil absorbency. The use of such a boron nitride powder provides a cosmetic significantly improved not only in gloss finish and transparency (bare skin feeling) but also in sustainability.

Abstract: A dental bleaching composition includes a dental bleaching agent, a binder, a tartrate, and a solvent.

Abstract: Methods and compositions for treating modulating and/or ameliorating non-light-induced, particularly non-UV-induced, skin aging in a human, for reducing the basal MMP-10 expression in unirradiated cells of an organism and/or reducing the basal MMP-1 RNA transcription and protein translation in unirradiated cells of an organism, and/or for modulating the effects of UVA-induced RNA transcription and polypeptide translation of a matrix metalloprotease, which include administering an effective amount of ?-carotene, a precursor of ?-carotene, a salt of ?-carotene, or a combination of two or more thereof to an organism, particularly a mammal, more particularly a human, in need thereof.

Abstract: Suggested are new flavour and fragrance compositions comprising selected acetophenone derivatives for dissolving flavours and fragrances, and further especially for dissolving lipophilic compounds, which are implemented in these products.

Abstract: The current document is directed to methods that ameliorate and/or reverse human hair-loss. The methods render hair follicles accessible to treatment agents that remove blocking oil and cell remnants to allow additional treatment agents to enter the pilosebaceous units to kill or control microbes that disrupt hair growth by changing, inhibiting, or interrupting one or more biological functions of the pilosebaceous units.

Abstract: The present invention relates to a composition for dyeing keratin fibres, in particular human keratin fibres, comprising one or more fatty substances, one or more surfactants, one or more oxidation bases, one or more particular couplers of meta-phenylenediamine type substituted in position 2, and one or more basifying agents, the fatty substance content in the dye composition representing in total at least 5% by weight relative to the total weight of the said composition. The invention also relates to a dyeing process using such a composition, and also to multi-compartment devices suitable for performing the said process.

Abstract: A cosmetic agent (A) is applied to the fibers and is allowed to act for a period of 30 seconds to 30 minutes, after which a cosmetic agent (B) is applied to the keratinic fibers, which continue to be acted on by agent (A). Both agents (A) and (B) are allowed to act for a period of 5 to 45 minutes, after which the agents (A) and (B) are rinsed out. Agent (A) (a1) contains no oxidation dye precursors of the developer type, (a2) contains one or more oxidation dye precursors of the coupler type, (a3) has a pH of 8.0 to 12.0, and agent (B) (b) contains one or more oxidation dye precursors, (b2) contains one or more oxidizing agents, and (b3) has a pH of 8.0 to 12.0.

Abstract: The present invention relates to compositions for and methods of retarding hair loss or facilitating hair growth comprising a hair growth active and a C8-C24 alcohol ester of a carboxylic acid.

Abstract: A composition and a process for straightening hair are disclosed. The process includes coating keratin fibers with a composition comprising a thermally-activated agent and contacting the coated keratin fibers with a heating device at a temperature of at least 185° C. for sufficient time to modify the keratin fibers. The thermally-activated agent comprises a heterocyclic compound containing two heteroatoms selected from nitrogen and oxygen in a 5 or 6-membered ring, such as a cyclic alkylene carbonate.

Abstract: The invention concerns a use of C7 sugars and derivatives of formula (I), called avocado perseose, which have, inter alia, a protective activity to epidermal skin cells. These C7 sugars and derivatives are capable of maintaining the expression of markers of adult stem cells, in particular basal stem cells. Avocado perseose can also be used for preventing the deleterious effects of environmental damage. Avocado perseose has a beneficial effect on the conservation of the potential of epidermal stem cells and thus helps maintain skin homeostasis.

Abstract: A tetrapeptide having antioxidant activity is provided. The tetrapeptide has a structure comprising, in amino acid sequence from N-terminus to C-terminus: tryptophan-X-tyrosine-X; wherein X is arginine, lysine, histidine or any positively-charged amino acid derivative such as 5-hydroxylysine, ornithine, 2,4-diamino-butyrate and 2,3-diamino-propionate. Each amino acid of the sequence or its Homo-amino acid derivative is independently of the D configuration (D-stereoisomer) or of the L configuration (L-stereoisomer), and the C-terminal comprises one selected from the group consisting of carboxyl (—COOH), and carboxamide (—CONH2). A composition stabilized to oxidation or having antioxidant activity and a method for attenuating effects of free radicals on a keratinous material are also provided.

Abstract: A topical cosmetic composition that includes a dermatologically acceptable carrier and an effective amount of a skin commensal prebiotic to improve the health of the skin microbiome, thereby potentially improving the condition and/or appearance of the skin. The topical cosmetic compositions may be made by identifying a potential skin commensal prebiotic agent using a first in vitro assay; confirming the prebiotic potential of an identified prebiotic agent with a second in vitro assay or an in vivo assay; and mixing a confirmed prebiotic agent from and a dermatologically acceptable carrier to form a topical cosmetic composition.

Abstract: Disclosed is a hair conditioning composition comprising: a mono-alkyl amine cationic surfactant; a high melting point fatty compound; an anionic polymer comprising higher % of a vinyl monomer (A) with a carboxyl group; and an aqueous carrier, wherein the composition has a pH of 4 or less. The present invention provides hair conditioning compositions having reduced chunks while containing both mono-alkyl amine cationic surfactants and anionic polymers containing higher % of vinyl monomer with carboxyl group.

Abstract: Methods of making personal care compositions including microcapsules and methods of enhancing the efficacy of the microcapsules in said personal care compositions.

Abstract: The invention concerns a compound formed by functionalised micro- or nanoparticles covalently associated with rheology-modifying polymers. The invention is characterised in that the functionalised micro- or nanoparticles are functionalised inorganic or metal oxide micro- or nanoparticles, in particular aluminium oxide (Al2O3), copper oxide (CuO), iron oxide (Fe3O4 or ?-Fe2O3), magnesium oxide (MgO), silica (SiO2), titanium dioxide (TiO2) or zinc oxide (ZnO), having a nominal diameter of between 1 and 1500 nm; and in that the rheology-modifying or -adapting polymers are chosen from non-associative polymers or associative polymers. The invention applies to protection or decontamination of the skin.

Abstract: A cosmetic composition useful to reduce the drying time of wet hair is disclosed. The composition includes a nonaqueous combination of a volatile silicone compound, such as cyclopentasiloxane, and a mixture of one or more silicone elastomers. The silicone elastomers may include, but are not limited to, dimethicone, cetearyl dimethicone crosspolymers, dimethicone crosspolymers, dimethicone/vinyl dimethicone crosspolymers, and dimethiconol.

Abstract: The present invention relates to an organopolysiloxane graft polymer including an organopolysiloxane segment as a main chain thereof and an unsaturated monomer-derived copolymer segment containing a repeating unit derived from an unsaturated monomer containing a carboxylic acid or a carboxylic acid salt as a side chain thereof, in which a content of the organopolysiloxane segment in the organopolysiloxane graft polymer is 35 to 59% by mass, a content of the repeating unit derived from the unsaturated monomer containing a carboxylic acid or a carboxylic acid salt in the organopolysiloxane graft polymer is 4 to 17% by mass, and a content of a repeating unit derived from an unsaturated monomer whose homopolymer has a glass transition point of not lower than 150° C.

Abstract: The embodied invention generally pertains to compositions, and the methods of making and using said compositions for promoting hair growth, slowing hair loss, and for preventing or minimizing hair loss that are effective and able to treat multiple aspects of the problem in one product and additionally is comprised of natural oils and minerals which greatly reduce the toxicities and side effect issues associated with present products. The compositions or formulations of the present invention relate to a hair loss solution that solves the problems associated with the loss, and damage of hair by working from the root to the surface of the scalp and to the hair shaft by treating a plurality of the causes and/or triggers associated with hair loss, or the prevention of hair re-growth.

Abstract: The present invention concerns the cosmetic and/or dermatological use of at least one essential oil of sweet orange to prevent and/or treat skin pigmentation disorders.

Abstract: A method of growing hair is disclosed. The method comprising: providing a plurality of date seeds; inserting the plurality of date seeds in an oven for a certain period of time; baking the plurality of date seeds in the oven; grinding the plurality of date seeds to form a paste; mixing the paste with a plurality of oils to form an oily paste; placing the oily paste in an environment to sit; and applying the oily paste to a head of at least one person to grow hair on the head of the at least one person.

Abstract: Disclosed are compositions and corresponding methods of their use that include jaboticaba fruit pulp and/or cashew fruit pulp or extracts thereof.

Abstract: Methods of using extracts of Tetracera asiatica to impart benefits to skin and/or improve skin conditions resulting from aging or damaged skin.

Abstract: Methods of using extracts of Hedyotis hedyotidea to impart benefits to skin and/or improve skin conditions resulting from aging or damaged skin.

Abstract: Methods of using extracts of Abutilon indicum to impart benefits to skin and/or improve skin conditions resulting from aging or damaged skin.

Abstract: Disclosed is a microneedle coating composition comprising a physiologically active substance (excluding Japanese encephalitis vaccine antigen), a basic amino acid, and an acid, wherein the mole number of the acid for one mole of the basic amino acid is larger than 1/(N+1) and less than 2, where N represents the valence of the acid.

Abstract: Selected anticholinergic zwitterions are administered to slow the progression of myopia in children and to treat myopia generally.

Abstract: The present invention relates to chewable compositions for oral administration, said compositions comprising high(methyl)pectin, glycerol and water. Advantageously, the chewable composition can comprise a drug substance. The present invention also concerns a process for preparing the chewable composition and the use of said chewable composition as a medicament.

Abstract: Dry powder formulations for inhalation and their use in the treatment diseases and conditions. The formulation contains a uniform blend of a first spray-dried powder and a second spray-dried powder. The first spray-dried powder contains spray-dried particles of a therapeutically active ingredient dispersed in a pharmaceutically acceptable hydrophobic excipient. The second spray-dried powder contains spray-dried particles formed from a pharmaceutically acceptable hydrophobic excipient but are substantially free of any therapeutically active ingredient. The active ingredient in the first spray-dried powder is loaded sufficiently high to compensate for the second spray-dried powder being substantially free of any active ingredient. A process for preparing such formulations is also described.

Abstract: The present invention relates to an infusion product for making a beverage, more specifically to a plant-based composition for making a beverage, and to a herbal and/or vegetable composition or bouquet garni. The plants are fruits, herbs, medicinal plants, tea, vegetables and/or spices. The invention further relates to a method for producing said compositions or infusion product, its use for making a (tea) beverage, and a (tea) beverage so obtained. Further, the present invention relates to a fiber-web, preferably a tea bag, made from said fruits, herbs, medicinal plants, tea, vegetable and/or spices.

Abstract: A substantially surface active agent-free and substantially polymeric agent-free foamable composition which includes short-chain alcohol, water, fatty alcohol or fatty acid or a combination of fatty alcohol and fatty acid and propellant. A substantially surface active agent-free and substantially polymeric agent-free foamable composition which includes water, fatty alcohol or fatty acid and propellant. A method of treatment using a substantially surface active agent-free and substantially polymeric agent-free foamable composition.

Abstract: The composition of the invention, liposomal glutathione, has been recently shown to have utility for having an antibiotic like effect on Klebsiella pneumonia cultures in vitro, and in vivo as demonstrated by efficacy in reducing by large multiples the presence of cultures of Klebsiella in rats in animal tests. Further, because the liposomal glutathione bolsters body defenses as well as appearing to have direct killing action, the propensity to create more and more resistant strains to antibiotic treatment is downgraded.

Abstract: The present invention relates to a poly(lactic glycolic) acid (PLGA) nanoparticle associated with therapeutic agents for a variety of therapeutic applications.

Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Abstract: A method for formation of micro-prilled poloxamer particles is disclosed. The particles find special use in pharmaceutical formulations. The process involves use of atomizing nozzles at higher than normal pressure atomizing gas, high atomizing gas temperature, use of high feed temperatures to reduce the viscosity of the poloxamer and optionally sieving after prill formation in prilling towers. The poloxamer particles are spherical and preferably have an average nominal diameter of less than or equal to 106 microns. The process is very cost effective and rapid.

Abstract: The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one or more physiologically acceptable auxiliary substances (B) and optionally a synthetic, semi-synthetic or natural wax (D), wherein the dosage form exhibits a resistance to crushing of at least 400 N and wherein under physiological conditions the release of the physiologically active substance (A) from the dosage form is at least partially delayed.

Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Abstract: To provide an enteric coated tablet containing a large amount of medicinal ingredient and having sufficient impact resistance, without forming a thick enteric coating layer. The enteric coated tablet contains (A) a core tablet containing a medicinal ingredient and having a weight of 1,000 mg or more; (B) a coating layer containing a water-soluble polymer applied onto the surface of the core tablet; and (C) an enteric coating layer dissolving at pH 7 or higher which is applied onto the surface of the coating layer containing a water-soluble polymer, wherein the sum of the polymer amount of the coating layer (B) and the polymer amount of the coating layer (C) is 10 to 18 mg/cm2, the polymer amount of the coating layer (B) is 6 to 12 mg/cm2, and the polymer amount of the coating layer (C) is 3 to 6 mg/cm2.

Abstract: A method for sustained delivery of an agent to an ocular organ in a subject, comprising topically delivering to the ocular surface a liquid thermoresponsive hydrogel comprising agent-loaded polymer microparticles, wherein the agent is sustainably released for a period of at least five days.

Abstract: The present invention relates to compositions and methods to treat and/or prevent biofilms and biofilm related diseases. The invention comprises a nanoparticle carrier (NPC) and at least one therapeutic agent therein. The NPC binds within biofilm and to surfaces at risk for biofilm formation and accumulation while providing local, sustained, enhanced and controlled delivery of the therapeutic agent, when triggered for release. In one embodiment, the NPC comprises pH-responsive elements that allows for specific delivery of the therapeutic agent when the local environment dictates that the agent should be delivered precisely when it is most needed.

Abstract: The invention relates to liquid pharmaceutical formulations for oral administration with the modified release of active principle(s), excluding amoxicillin, said formulations consisting of suspensions of coated particles of active principles (microcapsules). According to the invention, the microcapsules constituting the disperse phase of the suspension are designed to allow the modified release of the active principle(s) according to a profile that does not change during the storage of the liquid suspension. To do this the inventors propose the selection of a specific coating composition for the microcapsules which consists of at least four components that allow these microcapsules to be stored in water without modifying their properties of modified release of the active principle, this liquid phase furthermore being saturated with active principle(s).

Abstract: The invention relates to liquid pharmaceutical formulations for oral administration with the modified release of active principle(s), excluding amoxicillin, said formulations consisting of suspensions of coated particles of active principles (microcapsules). According to the invention, the microcapsules constituting the disperse phase of the suspension are designed to allow the modified release of the active principle(s) according to a profile that does not change during the storage of the liquid suspension. To do this the inventors propose the selection of a specific coating composition for the microcapsules which consists of at least four components that allow these microcapsules to be stored in water without modifying their properties of modified release of the active principle, this liquid phase furthermore being saturated with active principle(s).

Abstract: Some embodiments of the present disclosure include an encapsulated islet for treating diabetes. The encapsulated islet may include a semi-permeable capsular membrane having a plurality of layers including an outer immunoprotection layer, a bridging layer, and an inner backbone layer, each layer having a plurality of pores, wherein the pores increase in size from the immunoprotection layer to the backbone layer, creating the tapered conduits. The semi-permeable capsular membrane may include the following layers, in order from outermost layer to innermost layer: an immunoprotection layer, a bridging layer, and a backbone layer. With proper balancing of membrane thickness and tapered pore size distribution, the encapsulated islets may offer a diabetes treatment or functional cure without immunosuppressive drugs.

Abstract: An oral composition comprising minicapsules wherein the minicapsules comprise one or more therapeutic or prophylactic substances in a liquid, semi-liquid, or solid core. The minicapsules have release profiles to release the substance in an active form at one or more sites along the gastro-intestinal tract to maximise absorption and/or therapeutic efficiency.

Abstract: An encapsulated hydrophilic antiretroviral drug including a biodegradable polymeric nanoparticle and a process for fabricating biodegradable polymeric nanoparticles to encapsulate hydrophilic antiretroviral drugs are described. In an implementation, an encapsulated hydrophilic antiretroviral drug including a biodegradable polymeric nanoparticle includes a hydrophilic antiretroviral drug; and a biodegradable polymer polymeric nanoparticle that encapsulates the hydrophilic antiretroviral drug to form a nano-sized encapsulated hydrophilic antiretroviral drug.

Abstract: The present invention relates to water-soluble films incorporating anti-tacking agents and methods of their preparation. Anti-tacking agents may improve the flow characteristics of the compositions and thereby reduce the problem of film adhering to a user's mouth or to other units of film. In particular, the present invention relates to edible water-soluble delivery systems in the form of a film composition including a water-soluble polymer, an active component selected from cosmetic agents, pharmaceutical agents, vitamins, bioactive agents and combinations thereof and at least one anti-tacking agent.

Abstract: The present invention relates to a pharmaceutical composition for forming a film directly on a wound to accelerate wound healing, a use for the same, a treatment method using the same, and a method for preparing the same. The film-forming composition according to the present invention forms a film directly on the wound to increase the adhesion to the wound. The formed thin hydrophilic film protects the wound surface to prevent infection of the wound surface, retains the physiologically active substance useful for wound healing on the wound surface to promote the wound healing, and allow drugs to be continuously delivered to the wound surface. Therefore, the composition according to the present invention has excellent wound healing effect and has excellent usability as it is not absorbed into clothing, bandage, etc., thus effectively replacing conventional gel or ointment formations for delivering physiologically active substances.

Abstract: A patch containing a storage layer retaining a drug or a pharmaceutically acceptable salt thereof and an adhesive layer which are formed on a support, wherein the adhesive layer contains a thermoplastic elastomer, and a non-volatile hydrocarbon oil in more than 50 parts by weight and not more than 800 parts by weight per 100 parts by weight of the elastomer, and the adhesive layer optionally further contains a tackifier at a content of not more than 10 wt %.

Abstract: A composition for inducing differentiation into beige adipocytes from white adipocytes, including butein, a butein derivative, or a pharmaceutically available salt thereof as an active ingredient, and a method of inducing the differentiation are provided. Increases in expressions of UCP-1 and PRDM4 are confirmed using the active ingredient, that is, the butein or butein derivative, and therefore the composition is expected to be used in preventing or treating obesity, and more basically, for target treatment.

Abstract: A composition for the treatment of perianal disorders. In particular, the composition includes three components: a) an analgesic, b) a cryoprotective agent and c) a muscle relaxant.